Good solid presentation. Will be much the same this evening no doubt. I'm not sure what folk were expecting AS to say really. That Medusa19 will start selling the LFT at 8.30 am next Monday? That we've just got FDA approval for our LFT? That the AVA6000 clinical trial will be completed with good results by the end of July? No price-sensitive information will ever be given in an investor webinar.
I was pleased to have the chance to top-up x2 during the presentation. Thank you MM, and impatient sellers!
RE: HM Gov Presentation on testing today 1PM10 Jun 2020 14:37
Just watched this. No mention of Avacta, but they will ne aware no doubt. I guess until there is an RNS saying the LFD is ready to launch "Avacta" cannot really be mentioned by name. It's worth watching the webinar though if you want to learn more about the state of play of testing in the NHS - admittedly a smallish market in worldwide terms but good for AVCT PR if we were able to supply the LFD here. The webinar and slides will be made available to watch - but I'm not sure where. Does anybody here know?
NHS seeks another huge increase in testing capacity09 Jun 2020 15:22
This piece has just been included in Health Services Journal. The first couple of paragraphs read :
"The NHS has been told to increase its covid-19 swab testing capacity again by at least double, HSJ has learned, including via efforts to expand rapid-turnaround tests. Pathology chiefs across England have been asked to ensure each network of laboratories can process 3,000 PCR swab tests daily, although it is not clear on what timeline this is to be achieved. HSJ also understands efforts to ramp up the number of PCR tests which can be turned around quickly — within an hour or four hours — are part of this objective, but are being hampered by a shortage of chemical reagents".
I won't post the whole article as the HSJ needs a subscription although they are providing COVID-19 articles free if you register for them. See - https://www.hsj.co.uk
No Monkshead, they are not. At least not in the. NHS, whose labs I worked in for 35 years. Not an expert in MS though, far from it. As you say MS machines can be expensive bits of kit, and a sound case of need based on clinical demand will have had to be made to get them purchased in the first place. I assume the same sort of thing will hold in the rest of the world, where of course there are different ways of funding healthcare compared to our beloved NHS. Having said all that, in the face of a pandemic no doubt work patterns and time would be modified to free up MS time for eg covid testing.
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Alastair Smith, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that a BAMS(TM) diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix (Beverly MA, USA), has reached prototype stage and can detect the coronavirus spike protein in model samples in the concentration range appropriate for a clinical diagnostic test.